Related Experiment Video

Updated: Jun 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Jianbiao Zhou1, Boon-Cher Goh, Daniel H Albert

  • 1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. mdczjb@nus.edu.sg

Journal of Hematology & Oncology
|August 1, 2009
PubMed

Insights

ABT-869, a novel tyrosine kinase inhibitor (TKI), shows promise in treating solid tumors by inhibiting key growth factor receptors. Clinical trials indicate efficacy and manageable side effects, with ongoing research exploring resistance mechanisms.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tyrosine Kinase Inhibitors (TKIs) have revolutionized cancer therapy.
  • Aberrant tyrosine kinase (TK) signaling is a hallmark of many cancers.
  • Novel TKIs are crucial for advancing cancer treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of ABT-869, a novel ATP-competitive receptor tyrosine kinase inhibitor.
  • To investigate the anti-tumor properties of ABT-869 in vitro and in vivo.
  • To explore the potential of ABT-869 in combination therapies and identify predictive biomarkers.

Main Methods:

  • In vitro studies assessing antiproliferative and apoptotic effects.
  • In vivo studies using cancer xenograft models.
  • Phase I clinical trial in patients with solid tumors.
  • Correlative laboratory studies for biomarker analysis.
  • In vitro studies to identify resistance mechanisms.

Main Results:

  • ABT-869 demonstrated potent antiproliferative and apoptotic effects in preclinical models.
  • Phase I trial showed efficacy in lung and hepatocellular carcinoma with manageable side effects.
  • Evidence of antiangiogenic activity was observed through tumor cavitation and reduced contrast enhancement.
  • Combination therapy with chemotherapy or mTOR inhibitors showed additive effects.
  • Novel resistance mechanisms to ABT-869 were identified.

Conclusions:

  • ABT-869 is a promising TKI with demonstrated efficacy in solid tumors.
  • ABT-869 exhibits antiangiogenic properties and potential for combination therapy.
  • Biomarker studies may aid in patient selection for future trials.
  • Understanding resistance mechanisms is vital for optimizing TKI therapy.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...